Vertex Pharmaceuticals Inc. (VRTX)

Meridian Wealth Management LLC Has $323,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Meridian Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 794 shares of the pharmaceutical company’s stock after purchasing an additional 31 shares during the quarter. Meridian Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $323,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds also recently made changes to their positions in VRTX. Arlington Trust Co LLC grew its stake in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares during the period. Fortitude Family Office LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $30,000. Baystate Wealth Management LLC lifted its position in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares in the last quarter. NBC Securities Inc. acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth about $34,000. Finally, Asset Dedication LLC boosted its position in Vertex Pharmaceuticals by 131.8% during the 3rd quarter. Asset Dedication LLC now owns 102 shares of the pharmaceutical company’s stock worth $35,000 after acquiring an additional 58 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock. Analyst Upgrades and Downgrades A number of analysts have recently commented on the stock. Wolfe Research initiated coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $462.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. JPMorgan Chase & Co. upped their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Sanford C. Bernstein cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. Finally, StockNews.com raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $432.18. Get Our Latest Analysis on Vertex Pharmaceuticals Insider Activity at Vertex Pharmaceuticals In other news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is currently owned by corporate insiders. Vertex Pharmaceuticals Stock Up 1.0 % VRTX stock opened at $445.21 on Monday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $320.01 and a fifty-two week high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. The stock has a market capitalization of $114.89 billion, a price-to-earnings ratio of 28.89, a PEG ratio of 2.13 and a beta of 0.39. The business’s fifty day moving average price is $409.75 and its two-hundred day moving average price is $404.53. Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, topping the consensus estimate of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. During the same quarter in the previous year, the company earned $2.67 EPS. The business’s revenue was up 13.3% on a year-over-year basis. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.28 earnings per share for the current year. About Vertex Pharmaceuticals (Free Report) Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.